Eli Lilly shares have cooled from their multi-year surge, with the stock up about 410% over the past five years and roughly 58% over the last 52 weeks, but up only about 10.1% so far this year. The gap versus the broader U.S. market has narrowed investors’ focus to valuation and the durability of the company’s leadership in GLP-1-based therapies.
Data cited by the article points to a premium valuation—Lilly is trading at roughly 40 times trailing earnings—suggesting that expectations for continued product momentum may already be priced in. The stock’s relative underperformance also comes as the S&P 500 has gained around 12.5% year-to-date.
Key takeaways
- Price move: Eli Lilly shares have risen strongly over five years, but the stock is up about 10.1% year-to-date, lagging the S&P 500’s roughly 12.5% gain.
- Catalyst: The article attributes the slower pace primarily to an expensive starting valuation following prior steep gains.
- Business driver: Lilly’s tirzepatide leadership in GLP-1 and related weight-loss and diabetes markets remains a key support.
- Market implication: Wall Street remains broadly constructive, with most analysts recommending “buy” or “strong buy,” though forecasts reflect a range of views on future growth durability.
What drove the shift in Lilly’s stock performance
The article says the deceleration in Eli Lilly’s climb is likely tied to how much ground the stock has already covered. After gains of about 410% over five years, the shares are described as trading at approximately 40 times trailing earnings, a level that can limit upside when growth expectations are met or when investors rotate toward other parts of the market.
In that context, investors appear to be comparing what Lilly’s current valuation implies versus what the broader market is delivering. The S&P 500 is noted as having gained around 12.5% in 2026, while Lilly’s year-to-date increase of about 10.1% has left it behind the index.
Lilly’s GLP-1 franchise remains central
Despite the stock’s slower year, the article emphasizes Lilly’s product position in the GLP-1/GLP-1 dual agonist space. It cites that in the third quarter of 2025, Lilly’s tirzepatide—described as a GLP-1 dual receptor agonist—overtook Merck’s Keytruda as the top-selling drug worldwide.
The article also frames Lilly’s tirzepatide as being sold under two key brands: Mounjaro for type 2 diabetes and Zepbound for weight loss.
On market expectations for the category, the article references projections from Morgan Stanley that the GLP-1 drug market could reach $190 billion by 2045, more than double the 2025 level. It attributes an increased forecast—by $40 billion—to the launch of oral therapies and an expansion of Medicare coverage in the United States.
Wall Street views: broadly bullish, but not unanimous
According to the article’s summary of analyst targets, Wall Street remains positive on Eli Lilly, though the outlook is not uniform. The average price target cited is $1,325, which the article says is about 11% above a referenced current price of $1,193.
The article also states that among 30 major analysts covering Lilly, 25 recommend “buy” or “strong buy.” It highlights two contrasting examples: Citigroup is described as the most bullish, with a “buy” rating and a price target of $1,600, while HSBC is described as the most bearish, with a target of $940 and a “reduce” recommendation.
The article suggests some analysts may be concerned that Lilly’s dominance in GLP-1 could face longer-term pressure. It points to competition from Novo Nordisk, including its oral GLP-1 weight loss drug referred to as Wegovy. At the same time, the article argues Lilly has protective factors, including patents extending into the late 2030s and follow-on patents related to delivery devices, formulations, and treatment methods.
Bigger picture: valuation versus category growth
Taken together, the article frames the current debate around two forces. On one hand, GLP-1 and related therapies have expanding demand drivers—such as oral formulations and broader insurance coverage—supporting longer-term growth expectations for the category. On the other hand, Lilly’s valuation—described as around 40 times trailing earnings—raises the bar for near-term execution and may contribute to a stock that grows more slowly once investors have already priced in substantial momentum.
For investors, the key question is whether Lilly can sustain leadership and manage competition while delivering growth strong enough to justify a premium multiple as the market’s broader benchmark continues to advance.
What to watch next: Investors will likely focus on upcoming quarterly updates from Eli Lilly for evidence on demand trends, competitive dynamics in GLP-1 and oral therapies, and any guidance on forward growth. The next set of company results—and broader market catalysts that can shift expectations for growth stocks, including interest-rate signals and major economic data—could determine whether the stock’s year-to-date underperformance persists or reverses.
